Literature DB >> 31317306

Correction to: Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma.

Changhui Li1, Bo Zhang1, Jindong Guo2, Fang Hu1, Wei Nie1, Xiaoxuan Zheng1, Lixin Wang3, Yuqing Lou1, Yinchen Shen1, Baohui Han4, Xueyan Zhang5.   

Abstract

The article Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinom, written by Changhui Li, Bo Zhang, Jindong Guo, Fang Hu, Wei Nie, Xiaoxuan Zheng, Lixin Wang, Yuqing Lou, Yinchen Shen, Baohui Han, Xueyan Zhang, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 03 July 2019 with open access. With the author(s)' decision to step back from Open Choice, the copyright of the article changed on 17 July 2019 to © Springer Nature Switzerland AG 2019 and the article is forthwith distributed under the terms of copyright.

Entities:  

Year:  2019        PMID: 31317306     DOI: 10.1007/s11523-019-00659-z

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  1 in total

1.  Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.

Authors:  Changhui Li; Wei Nie; Jingdong Guo; Anning Xiong; Hua Zhong; Tianqing Chu; Runbo Zhong; Jianlin Xu; Jun Lu; Xiaoxuan Zheng; Bo Zhang; Yinchen Shen; Feng Pan; Baohui Han; Xueyan Zhang
Journal:  Respir Res       Date:  2021-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.